Ranitidine Bismuth

雷尼替丁枸橼酸铋

Report date: 2023/03/16 20:00:26
NME

Base Information

Drug NameRanitidine Bismuth
Drug Alias Name枸橼酸铋雷尼替丁Ranitidine Bismutrex CitrateTritecPyloridGR-122311X
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H2 receptor antagonists
TargetsHistamine H2 receptor
Therapy Area/IndicationsHelicobacter pylori infectionStomach UlcerDuodenal Ulcer +[4] 
Global Approved IndicationsHelicobacter pylori infectionStomach UlcerDuodenal Ulcer +[4] 
Approved Indications in ChinaHelicobacter pylori infectionStomach UlcerDuodenal Ulcer
Original Approved Country/TerritoryUnited States
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcLivzon(Group) Pharmaceutical Factory
Inactive CompaniesGlaxo Wellcome Inc
Active IndicationsHelicobacter pylori infectionStomach UlcerDuodenal Ulcer +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeA02BA02
Related LinksWikipediaDrugBankKEGG